• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know
Royalty Pharma AG is a privately owned company which invests in royalty interests in pharmaceutical and biopharmaceutical products. The Company provides liquidity to royalty owners, and assumes the future risks and rewards of ownership.
Market Cap | 260.049 Million | Shares Outstanding | 388.132 Million | Avg 30-day Volume | 460.853 Thousand |
P/E Ratio | 39.2725 | Dividend Yield | 1.7967 | EPS | 1.26 |
Price to Revenue | 10.3826 | Debt to Equity | 0.7002 | EBITDA | 1.38 Billion |
Price to Book Value | 4.0946 | Operating Margin | 62.37200000000001 | Enterprise Value | 32.124 Billion |
Current Ratio | 21.95 | EPS Growth | -0.047 | Quick Ratio | 21.426 |
1 Yr BETA | 0.4538 | 52-week High/Low | 0.0 / | Profit Margin | 53.1188 |
Operating Cash Flow Growth | -6.6002 | Altman Z-Score | 2.7258 | Free Cash Flow to Firm | 360.255 Million |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
0 | 2020-06-16 | 0 | |
|
0 | 2020-06-15 | 0 | |
ADAGE CAPITAL PARTNERS GP, L.L.C. |
|
0 | 2020-06-15 | 0 |
|
0 | 2020-06-15 | 0 | |
|
0 | 2020-06-15 | 0 | |
|
0 | 2020-06-15 | 0 | |
LEGORRETA PABLO G. CEO, CHAIRMAN OF THE BOARD |
|
0 | 2020-06-15 | 0 |
|
0 | 2020-06-15 | 0 | |
HITE CHRISTOPHER EVP & VICE CHAIRMAN |
|
0 | 2020-06-15 | 0 |
REDDOCH JAMES F. EVP, RESEARCH & INVESTMENTS |
|
0 | 2020-06-15 | 0 |
COYNE TERRANCE P. EVP & CFO |
|
0 | 2020-06-15 | 0 |
SKYELINE MANAGEMENT LTD AVARA MANAGEMENT LTD NOGRA GROUP SICAF SIF MGG STRATEGIC NOGRA GROUP SICAF SIF GG STRATEGIC NOGRA GROUP SICAF - SIF S.A. SEVERGNINI ACHILLE G. |
|
0 | 2020-06-15 | 0 |
LLOYD GEORGE W. EVP, INVESTMENTS & GC |
|
0 | 2020-06-15 | 0 |
|
No longer subject to file | 2018-01-29 | 0 | |
|
No longer subject to file | 2018-01-29 | 0 | |
|
No longer subject to file | 2018-01-29 | 0 | |
ANDERSON KATHERINE CHIEF FINANCIAL OFFICER |
|
No longer subject to file | 2018-01-29 | 0 |
|
No longer subject to file | 2018-01-29 | 0 | |
|
No longer subject to file | 2018-01-29 | 0 | |
DILLAHA LARRY INTERIM PRESIDENT AND CEO |
|
0 | 2017-02-01 | 0 |
THOMPSON JAYE SEE REMARKS |
|
0 | 2016-07-05 | 0 |
WERNICKE J. F. CHIEF MEDICAL OFFICER |
|
0 | 2016-07-05 | 0 |
|
0 | 2015-05-28 | 0 | |
PODOLSKI JOSEPH PRESIDENT AND CEO |
|
0 | 2014-03-26 | 0 |
WIEHLE RONALD VP, RESEARCH AND DEVELOPMENT |
|
0 | 2014-03-26 | 0 |
|
No longer subject to file | 2013-03-15 | 0 | |
|
0 | 2012-06-13 | 0 | |
|
1,315,672 | 2011-04-19 | 0 | |
|
1,144,365 | 2011-02-24 | 0 | |
|
No longer subject to file | 2009-12-17 | 0 | |
|
0 | 2009-05-20 | 0 | |
|
0 | 2009-05-20 | 0 | |
|
0 | 2009-05-20 | 0 | |
VAN AS ANDRE MD, PHD CHIEF MEDICAL OFFICER |
|
10,410 | 2009-04-14 | 0 |
PLOTH LOUIS JR VP & CHIEF FINANCIAL OFFICER |
|
0 | 2009-02-18 | 0 |
LAMMERS PAUL PRESIDENT |
|
0 | 2009-02-18 | 0 |
|
0 | 2008-05-14 | 0 | |
|
0 | 2008-05-14 | 0 | |
|
2,277,956 | 2008-03-14 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No current insider transactions |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|
Holder | Issuer | Net Short Position | Position Date | Origin |
---|